



**FOR IMMEDIATE RELEASE:**

Jan. 17, 2018, at 10 a.m. (ET)

**CONTACT:**

Kate Crawford, ASCO

(571) 483-1366

[Kate.Crawford@asco.org](mailto:Kate.Crawford@asco.org)

Andrew Noble, AMP

(415) 722-2129

[anoble@amp.org](mailto:anoble@amp.org)

**CancerLinQ LLC Enters Collaboration with the Association for Molecular Pathology**

***Cooperation Will Harness Expertise from Emerging Field of Molecular Pathology  
to Broaden ASCO's CancerLinQ® Platform***

Alexandria, Va.—CancerLinQ LLC and the Association for Molecular Pathology (AMP), a global, molecular diagnostics professional society, have entered into a collaboration. AMP leadership and members will be applying the breadth of their knowledge to CancerLinQ®, the American Society of Clinical Oncology's (ASCO) health information technology platform designed to leverage the power of big data to help conquer cancer.

"Molecular pathology is a cornerstone of precision medicine, and we value the expertise of AMP on how molecular changes in individual tumors can impact cancer treatment," said CancerLinQ LLC Chief Executive Officer Kevin Fitzpatrick. "We are excited to have AMP join us in our quest to improve the quality and value of care for people living with cancer."

Founded in 1995, AMP has more than 2,300 members from academic and community medical centers, government, and industry in professions that include pathologist and doctoral scientist laboratory directors, basic and translational scientists, technologists, and trainees. Drawing on this wealth of expertise, AMP is a resource for education and collaboration in the field of molecular pathology. The Association also works with its members to advance policy, regulation, and innovation in this field, as well as patient access to high-quality applicable testing.

"With CancerLinQ®, ASCO is enabling the oncology community to apply the full power of real-time patient data and analytics to transform cancer care," said AMP Past President and Chief Medical Officer of Castle Biosciences Federico A. Monzon, MD, FCAP. "Molecular testing is critical to selection of appropriate treatment in many cancers, and AMP looks forward to contributing our expertise to ensure

that the oncology community has a comprehensive resource to help deliver higher-quality care that incorporates molecular biomarker information."

Dr. Monzon will serve as AMP's representative on the CancerLinQ® Oncology Leadership Council, the strategic advisory body comprised of all official partner organizations that guides the growth and direction of CancerLinQ. AMP will have the ability to access CancerLinQ Discovery™—which provides access to curated sets of statistically de-identified clinical data from the CancerLinQ® platform—for the society's internal learning about and analysis of the current, real-world state of cancer care.

The collaboration with AMP is one of many that CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has entered into with a coalition of partners and thought leaders, including government agencies, medical specialty societies, and life sciences companies. Since 2016, the [American Academy of PAs](#), [American Society of Radiation Oncology](#), [Cancer Informatics for Cancer Centers](#), [College of American Pathologists](#), [DIA](#), [Food and Drug Administration](#), [Hematology/Oncology Pharmacy Association](#), [National Cancer Institute](#), [National Society of Genetic Counselors](#), [Oncology Nursing Society](#), and [Society of Gynecologic Oncology](#) have joined forces with CancerLinQ LLC. Additionally, [in November 2016](#), AstraZeneca became a founding enterprise partner with CancerLinQ Discovery™. These partnerships offer the CancerLinQ® team guidance and insights that ultimately can contribute to the quality and efficiency of the cancer care delivery system.

ASCO also has worked with AMP on other initiatives, including a new, evidence-based clinical practice guideline on molecular marker testing for patients with colorectal carcinoma that identifies opportunities for improving patient outcomes. The "[Molecular Biomarkers for the Evaluation of Colorectal Cancer Guideline](#)," which was co-authored with the American Society for Clinical Pathology and College of American Pathologists, was published in February of 2017 in *The American Journal of Clinical Pathology*, *Archives of Pathology and Laboratory Medicine*, *The Journal of Molecular Diagnostics*, and *Journal of Clinical Oncology*.

CancerLinQ® and CancerLinQ Discovery™ are projects of CancerLinQ LLC. For more information on how to participate or partner with CancerLinQ, please visit [CancerLinQ.org](#).

CancerLinQ® is supported in part through the [Conquer Cancer Foundation](#), whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD and Susan M. DaSilva; and Susan G. Komen®.

# # #

#### **About ASCO**

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world's leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at [www.ASCO.org](#), explore patient education resources at [www.Cancer.Net](#), and follow us on Facebook, Twitter, LinkedIn, and YouTube.

### **About CancerLinQ LLC**

CancerLinQ LLC is a subsidiary of American Society of Clinical Oncology, Inc. established for the development and operation of the CancerLinQ® initiative. CancerLinQ® is a health information technology platform aimed at enhancing and improving the understanding and treatment of cancer. To learn more, visit [www.cancerling.org](http://www.cancerling.org).

### **About AMP**

The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,300+ members practice in the various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions and oncology. They include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit [www.amp.org](http://www.amp.org). Follow AMP on Twitter: [@AMPath](https://twitter.com/AMPath).